🇺🇸 CMP 001 in United States

9 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Lymphocyte Count Decreased — 2 reports (22.22%)
  2. Colitis — 1 report (11.11%)
  3. Condition Aggravated — 1 report (11.11%)
  4. Granulomatous Lymphadenitis — 1 report (11.11%)
  5. Haematoma — 1 report (11.11%)
  6. Laryngeal Oedema — 1 report (11.11%)
  7. Malignant Neoplasm Progression — 1 report (11.11%)
  8. Treatment Failure — 1 report (11.11%)

Source database →

CMP 001 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is CMP 001 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for CMP 001 in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.